As reported in the Journal of Clinical Oncology by Jeffrey S. Weber, MD, PhD, and colleagues, the phase III CheckMate 915 trial showed no improvement in recurrence-free survival with adjuvant nivolumab/ipilimumab vs nivolumab in patients with resected stage IIIB–D or IV melanoma.
Clinical Trials
IO Before BRAK/MEK Inhibition Is the Ideal Treatment Sequence for BRAF-Mutant Melanoma
Data from the DREAMseq trial have answered a lingering question of how to sequence therapy for patients with advanced BRAF-mutant melanoma. This research supports immunotherapy in the first-line setting, followed by BRAK/MEK inhibitors.
Targeted Therapy Combinations Provide Multiple Treatment Options in BRAF-Mutated Melanoma
Jeff Yorio, MD, discussed the decision-making process for treating patients with BRAF-mutant melanoma, the use of immunotherapy in melanoma, and the management of cutaneous squamous cell carcinoma and basal cell carcinoma.
Sequential Immunotherapy and Targeted Therapy Shows OS Benefit in BRAF+ Melanoma
Three different sequencing schemas for immunotherapy followed by targeted therapy in patients with BRAF V600-mutant melanoma have shown positive survival outcomes and safety consistent with results from prior studies.